Our real-world findings indicate that most patients undergoing multiple lines of therapy experience persistent treatment refractoriness and low response rates,” the researchers wrote.

Melphalan flufenamide (melflufen) is approved in Europe for relapsed/refractory multiple myeloma, but the FDA withdrew its ...

A 59-year-old woman presented to the emergency department with a left rib fracture and was diagnosed with IgA multiple myeloma ... in patients with refractory myeloma. This case illustrates ...

There was also a trend towards improved overall survival (OS) in the study, which involved patients with relapsed/refractory multiple myeloma previously treated with at least one prior line of ...

Panelists discuss how recent clinical trials have demonstrated promising outcomes in late-line relapsed/refractory multiple myeloma (RRMM) with bispecific antibodies targeting B-cell maturation ...

Panelists discuss how treatment selection for late-line relapsed/refractory multiple myeloma (RRMM) balances multiple factors including patient fitness, prior therapy exposure, disease aggressiveness, ...

said the OS results "underscore the potential for this Blenrep combination to extend the lives of patients with relapsed/refractory multiple myeloma." He added: "This is a statistically ...

This CAR helps the T cells recognize and destroy cells expressing BCMA, which is primarily found in malignant multiple myeloma B-lineage cells, late-stage B cells, and plasma cells. The CARVYKTI ...